Talk Bio

Lyell Immunopharma Initiates First Head-to-Head Phase 3 CAR T-Cell Trial for Aggressive Large B-Cell Lymphoma

FDA Signals Higher Efficacy Bar for New CAR‑T Cancer Therapies